Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

This study tests whether two drugs — dasatinib and quercetin — can help overcome chemotherapy resistance in triple-negative breast cancer (TNBC) that has spread to other parts of the body. These drugs target aging or "senescent" cells that may be helping the cancer resist treatment. **You may be eligible if...** - You are an adult with metastatic or locally advanced triple-negative breast cancer (a type that lacks estrogen, progesterone, and HER2 receptors) - Your cancer has progressed or returned after prior chemotherapy - You have measurable cancer on imaging (based on standard criteria) - You are in good general health (ECOG score 0 or 1) - You agree to use effective contraception if you are of childbearing potential **You may NOT be eligible if...** - You have active or worsening cancer that has spread to the brain - You have had another cancer (other than breast cancer) within the past 5 years - You have significant heart disease - You have an autoimmune condition or immune deficiency - You are pregnant, breastfeeding, or planning to become pregnant - You received chemotherapy, radiation, or surgery within 3 weeks of starting the study Talk to your doctor to see if this trial is right for you.